Objective To investigate the clinical effect of Qiangli Dingxuan Tablets combined with flunarizine in treatment of cerebral arteriosclerotic vertigo.
Methods Patients (120 cases) with cerebral arteriosclerotic vertigo in Tianjin Ninghe Hospital from March 2017 to December 2019 were randomly divided into control (60 cases) and treatment (60 cases) groups. Patients in the control group were
po administered with Flunarizine Hydrochloride Capsules, 10 mg/time for less than 65 years old, and 5 mg/time for more than 65 years, once daily, 5 times/weekly. Patients in the treatment group were
po administered with Qiangli Dingxuan Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the symptom scores, and the mean flow velocity of the right vertebral artery, left vertebral artery and basilar artery in two groups before and after treatment were compared.
Results After treatment, the clinical efficacy in the control group was 76.67%, which was significantly lower than 91.67% in the treatment group, and there were differences between two groups (
P < 0.05). After treatment, the symptom scores of dysfunction of the vegetative nerve, hearing impairment, vertigo, balance disorders, headache and tinnitus in two groups were significantly decreased (
P < 0.05), and these scores in the treatment group were significantly lower than those in the control group (
P < 0.05). After treatment, the mean flow velocity of the right vertebral artery, left vertebral artery and basilar artery in two groups was significantly increased (
P < 0.05), and which in the treatment group was significantly higher than that in the control group (
P < 0.05).
Conclusion Qiangli Dingxuan Tablets combined with flunarizine in treatment of cerebral arteriosclerotic vertigo can rapidly improve the clinical symptoms and cerebral blood flow, which has a certain clinical application value.